Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Split-face Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris

NCT06729450 is registered in ClinicalTrials.gov with Kane Biotech Inc as lead sponsor.

NCT NCT06729450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06729450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Split-face Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris
Lead sponsor
Kane Biotech Inc
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 30, 2026
Completion date
December 16, 2026
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris on the face